Human Anti-IL-1α Antibodies With High-Affinity Variable Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack high-affinity human antibodies specifically targeting interleukin 1 alpha (IL-1α) for therapeutic applications, which are crucial for managing diseases involving sterile inflammation.
Innovation Solution
Development of fully human monoclonal antibodies (mAbs) with high binding affinity for IL-1α, comprising specific light and heavy chain variable regions, encoded by nucleic acids and expressed in host cells, which can be conjugated with therapeutic agents for targeted treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibody technologies are used, then general anti-IL-1α activity can be achieved, but high binding affinity and specificity for therapeutic applications cannot be obtained
Solution Approach 1:
The patent applies parameter changes by optimizing the amino acid sequences of the light and heavy chain variable regions of the antibody. Specific mutations and substitutions in the CDR regions were made to enhance binding affinity to human IL-1α while maintaining therapeutic suitability. The sequence optimization involved changing parameters such as hydrophobicity, charge, and steric properties of amino acids at key positions to achieve both high affinity and human compatibility.
2Reliability
If fully human monoclonal antibodies are developed, then therapeutic efficacy is improved, but development complexity and time increase
Solution Approach 1:
The patent employs preliminary action by pre-selecting and characterizing human antibody sequences with potential for high IL-1α binding affinity before full development. The light and heavy chain variable regions were identified and optimized in advance through sequence analysis and computational modeling, allowing for a more streamlined development process. This preliminary characterization of candidate sequences reduced the overall development complexity by focusing resources on the most promising candidates.
Data Source
AI summary
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.